Pharma, Health and Science Correspondent, Reuters
Pharma, health and science correspondent for Reuters in London. Any opinions are mine.
reuters.com — Credit: Reuters/Stringer Men wearing surgical masks as a precautionary measure against the novel coronavirus, speak at a hospital in Khobar city in Dammam May 23, 2013. Saudi Arabia, where the first case occurred, has said the development of diagnostic tests for the disease has been delayed by a foreign laboratory's patent rights on the SARS-like virus.
reuters.com — After years of being shunned, small biotechs are getting a closer look as equity investments even though many of them come to market before turning profit or delivering product to market. Indeed, 14 biotechs have gone public in 2013, marking the sector's best start since 2007, according to market data firm Ipreo.
reuters.com — Immunotherapy may be used in up to 60 percent of cancers * Bristol-Myers Squibb and Roche both upgraded to "buy" By Ben Hirschler LONDON, May 22 (Reuters) - A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with potential sales of $35 billion a year.
reuters.com — Credit: Reuters/Suzanne Plunkett A tray containing cancer cells sits on an optical microscope in the Nanomedicine Lab at UCL's School of Pharmacy in London May 2, 2013. The project, involving the Institute of Cancer Research (ICR) in London, the U.S.
reuters.com — Credit: Reuters/Paul Hackett/Files People walk into the quadrant of Clare College at Cambridge University in eastern England, in this October 23, 2010 file photo. Moving research and global headquarters to Cambridge, with minimal disruption, is a key test for new Chief Executive Pascal Soriot as he tries to change the drugmaker's culture and puts ground-breaking science at the center of its activities.
reuters.com — But to the psychiatrist who shepherded the tortuous creation of the "Diagnostic and Statistical Manual of Mental Disorders," perhaps the single most important number is the "5" in its title: This is the DSM-5, not the DSM-V.
reuters.com — Credit: Reuters/Pascal Lauener The logo of the Swiss drugmaker Roche is seen on a factory in Burgdorf near Bern November 17, 2010. Switzerland-based Roche aims to fend off cheaper competition for Rituxan, which loses patent protection in Europe later this year, threatening a product with nearly $7 billion in annual sales.
Have a Story?Send Pitch
Sign up to discover more journalists who cover Business and Finance, Science, Health, United Kingdom and more.Create An Account
Share This Profile